Clinical trials: Neoplasm, Oral
Head and Neck Cancer
Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome
This is a Phase II treatment, randomized 3:1 ratio, open label clinical trial to study the effect of short duration administration of N-acetyl cysteine on oral microbiome and on mucositis caused by concurrent chemotherapy and…
- Trial name
- NCT03982537
- Testing
- N-Acetyl-L-Cysteine dietary supplement, Chemotherapy and Radiation
- Sponsor
- Wake Forest University Health Sciences
Head and Neck Cancer
Acute and Longlasting Side Effects Caused by Radiotherapy in the Head and Neck Area
The purpose of this clinical investigation is to evaluate acute and longlasting side effects in patients undergoing radiotherapy for cancer treatment in the head and neck area.
- Trial name
- NCT00995319
- Where
- Norway
- Volunteers
- 58 people
- Sponsor
- Norwegian University of Science and Technology
Prostatic Neoplasms
Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer
The primary objective of this study was to determine the safety and Maximum tolerated dose (MTD) of BIBF 1120 combination therapy with docetaxel and prednisone in patients with hormone refractory prostate cancer.
- Trial name
- NCT02182219
- Testing
- BIBF 1120
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
Lymphoma, Leukemia
A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies
This study evaluated safety, tolerability, pharmacokinetics and preliminary anti-leukemic or anti-tumor activity of LBH589B in adult patients with advanced hematological malignancies
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma
- Trial name
- NCT00621244
- Testing
- LBH589
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals
Colorektal Cancer
Self-Management of Colon and Rectal Cancer Patients Receiving Oral Chemotherapy
Objective: This study aims to evaluate the effectiveness of a message-based intervention on self-management among patients with colorectal cancer receiving oral chemotherapy treatment. H1.
- Trial name
- Self Managemet (NCT07851675)
- Testing
- Messaging Intervention Effectiveness, control group
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Ozlem
Parotid Tumors, Facial Nerve Paresis
Intra-parotid Facial Nerve Imaging in Parotidectomy
In this study, the investigators will evaluate the clinical usefulness of 3 dimensional double echo steady state MRI (3D-DESS MRI) for functional preservation of the facial nerve during parotidectomy.
- Trial name
- NCT03822728
- Testing
- 3D-DESS MRI (3 dimensional double echo steady state MRI)
- Where
- South Korea
- Volunteers
- 270 people
- Sponsor
- Samsung Medical Center
Oral Cancer
Oral State of Patients Affected by an Oral Cancer Before and After Radiotherapy - 3-years Prospective Study
Context: the oral cancer is the 5th cancer in order of frequency for human in France. It is the country where the mortality by oral cancer is the most raised in Europe.
- Trial name
- VADS (NCT02866500)
- Testing
- Quality of life survey/ dental statement
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Central Nervous System Tumor, Pediatric, Leukemia
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
RATIONALE: Drugs used in chemotherapy, such as etoposide and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Central Nervous System Tumor, Pediatric, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00357500
- Testing
- celecoxib, cyclophosphamide, etoposide
- Where
- 10 sites in United States
- Volunteers
- 101 people
- Sponsor
- Dana-Farber Cancer Institute
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
This phase I trial studies the side effects and determines the best dose of genetically modified neural stem cells and flucytosine when given together with leucovorin for treating patients with recurrent high-grade gliomas.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT02015819
- Testing
- E. coli CD-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Gastrointestinal Cancer
Effects of Immunonutrition (Impact Oral®) in Patients Undergoing Surgery for Gastrointestinal Cancer
This study will evaluate the efficacy and safety of Impact Oral in Patients undergoing Surgery for Gastrointestinal Cancer, half of the participants will receive Impact Oral nutrition therapy, the other half will receive Enteral…
- Trial name
- NCT03665714
- Testing
- Impact Oral, Enteral Nutrition Emulsion(TPF-T)
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Société des Produits Nestlé (SPN)
Quality of Life, Oral Mucositis
Efficacy of a Probiotic and Microbiological Analysis on Oral Complications in Patients With HNC
The study is a Clinical Trial and the main objective is to Evaluate the effects of probiotics on oral complications induced by antineoplastic therapies in patients with head and neck cancer, attended at the radiotherapy service…
- Conditions
- Quality of Life, Oral Mucositis, Dental Plaque, Periodontal Diseases
- Trial name
- HNC (NCT06122636)
- Testing
- The probiotic to be used in the intervention corresponds to PRODEFEN Plus manufactured by ITALFARMACO S.A. laboratory
- Where
- Spain
- Volunteers
- 62 people
- Sponsor
- University of Barcelona
Head and Neck Cancer
Blood Sample Analysis in Predicting Overall Survival in Patients With Recurrent or Metastatic Head and Neck Cancer
RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898911
- Testing
- matrix-assisted laser desorption/ionization time of flight mass spectrometry
- Volunteers
- 30 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Oropharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma
Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.
The purpose of this project is to realize a randomized open-label study (EudraCT number: 2020-000120-19) to evaluate the safety and the anti-tumor activity of peptide(s)-based immunotherapy in an umbrella window pre-operative…
- Conditions
- Oropharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
- Trial name
- HN1901 (NCT04445064)
- Testing
- IO102, IO103
- Where
- Belgium
- Volunteers
- 17 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
T-cell Lymphoma
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma..
- Trial name
- NCT03952078
- Testing
- CPI-818
- Where
- 22 sites in United States, Australia and 2 more
- Volunteers
- 151 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Breast Cancer, Bone Marrow Suppression
A Randomized, Self-controlled Post-marketing Clinical Study on the Comparison of Shengbai Oral Liquid and Leucogen Tablets in the Treatment of Moderate Neutropenia Caused by Anti-tumor Drugs in Breast Cancer Patients
The subjects were randomly assigned to Group A or Group B in a 1:1 ratio, stratified by early/late stage. Group A: In the first cycle, they took Shengbai Oral Liquid (40 ml, three times a day), and in the second cycle, they took…
- Trial name
- NCT07578064
- Testing
- Group A, Group B
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hongxia Wang
Carcinoma, Non-Small-Cell Lung
An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)
This is a standard Phase 1b and 2a, multi-center, study design that will examine the safety, tolerability, and maximum tolerated dose of tivozanib (AV-951) with this dosing schedule, as well as overall response rate of tivozanib…
- Trial name
- NCT00826878
- Testing
- Tivozanib (AV-951)
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Lymphoma, Non-Hodgkin
A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15)
This phase I study is designed to evaluate absorption, metabolism and excretion (AME) profiles of [14C]-DZD8586, to determine the routes, rates of elimination, and mass balance of DZD8586 in healthy adult male participants.
- Trial name
- NCT07454863
- Testing
- DZD8586
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Dizal Pharmaceuticals
Glioblastoma, Rhabdomyosarcomas
ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors
The purpose of this Phase I study is to find the largest dose of the drug irinotecan, in combination with ZD1839, that can be given safely to children and to learn the good and bad effects.
- Conditions
- Glioblastoma, Rhabdomyosarcomas, Neuroblastoma, Osteosarcoma
- Trial name
- NCT00132158
- Testing
- Irinotecan (Camptosar), Gefitinib (Iressa)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- St. Jude Children's Research Hospital
Osteosarcoma, Spindle Cell Sarcoma of Bone
Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?
Methotrexate is one of the most effective chemotherapy drugs in the treatment of osteosarcoma and some other types of bone sarcoma which are treated the same way as osteosarcoma.
- Trial name
- NCT02022358
- Testing
- Glucarpidase, Methotrexate, Folinic Acid
- Where
- United Kingdom
- Volunteers
- 34 people
- Sponsor
- University College, London
Oral Squamous Cell Carcinoma
Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis
The trial is a single-center, non-randomized feasibility study aiming to evaluate the feasibility of ex-vivo tissue analysis using differential mobility spectrometry (DMS) of tissue smoke generated by the use of an…
- Trial name
- NCT05902455
- Testing
- Punch biopsy
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- Tampere University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.